"In a field starved for options, demand is exceeding supply for Wegovy, a weekly injection launched in June that dampens patients’ appetite and helps them lose about 15 per cent of their body weight. The Danish drug maker’s obesity-drug revenue surged by an unprecedented 41 per cent last quarter."
"Judging by analysts’ estimates, Wegovy will become a blockbuster next year, with annual revenue climbing to $US3.2 billion ($4.3 billion) in 2024. The drug works by mimicking a hormone called GLP-1 that targets areas of the brain that regulate appetite and food intake, and it is not without side effects. Patients report symptoms ranging from vomiting to acid reflux."
NYR Price at posting:
25.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)